touchREVIEWS in Neurology is an international, peer-reviewed, free-to-access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from ‘data-rich’ primary papers and provide practical advice and opinion. To further encourage discussion and learning, original research articles are welcomed across the clinical landscape, including observational, real-world and health outcomes studies. Editorials, case reports, commentaries and practice pearl articles are also featured.
The journal is of interest to clinicians, healthcare professionals and researchers as it provides practical advice relevant to the everyday clinical setting regarding the diagnosis and treatment of neurological conditions. touchREVIEWS in Neurology endeavours to support these professionals in continuously developing their knowledge, effectiveness and productivity.
Electronic ISSN: 2752-5465 DOI: doi.org/10.17925
Editors-in-Chief: Said R Beydoun and Cris S Constantinescu
Established: January 2006 Frequency: Annual
Title History: Formerly US Neurology (2006-2019) (Print ISSN: 1758-4000 Electronic ISSN: 1758-4019)
Abstracting and Indexing: touchREVIEWS in Neurology is abstracted, indexed and listed in SCOPUS, ICI Journals Master List database for 2024, EMBASE, EBSCO, and Google Scholar.
Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 ...
Spinal muscular atrophy (SMA, 5q-SMA) is a rare autosomal recessive neuromuscular disease characterized by progressive muscle weakness and atrophy resulting from degeneration of lower motor neurons located in the anterior horn of the spinal cord and specific brainstem nuclei.1 It ...
This article examines the role of ozanimod in the treatment of relapsing multiple sclerosis (RMS), summarizing relevant clinical trial data with a focus on efficacy, safety and long-term outcomes. These findings are discussed alongside practical and clinical considerations to place ...
The 12th European Stroke Organisation Conference (Maastricht, May 6–8, 2026) was dominated by studies testing the limits of acute stroke therapy, from thrombectomy and neuroprotection to secondary prevention. Supplementary Table 1 provides a comprehensive overview of the major studies presented during the conference. ...
Both intracerebral hemorrhage and ischemic stroke continue to be the leading causes of disability and the second leading causes of death worldwide.1,2 The burden is largest in low- and middle-income countries, which have seen rapid recent population growth. Large vessel ...
In this narrative review, we aim to introduce the reader to the history of calcitonin gene-related peptide (CGRP) discovery and its involvement in migraine pathophysiology. We will then look at drug development and clinical trials in migraine. We will additionally ...
Why this topic matters Autoimmune psychosis (AP) is conceptualized as a psychosis-dominant form of autoimmune encephalitis (AE). In contrast to ‘typical’ AE, in which seizures, impaired consciousness and focal deficits rapidly declare a neurological syndrome, patients with AP can initially ...
Alzheimer’s disease (AD), the most prevalent cause of dementia, is a progressive neurodegenerative disorder marked by the abnormal accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. It currently affects more than 50 million individuals worldwide, with projections reaching over 210 ...
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer’s disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 ...
Huntington’s disease (HD) is a fatal, autosomal-dominant, neurodegenerative disorder caused by a cytosine–adenine–guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene, located on chromosome 4p16.3. When this repeat exceeds 36 units, it leads to the synthesis of ...
In general, headaches can be classified into primary headaches (where no underlying disease is found) and secondary headaches (where a predefined condition is the cause of the headache). According to the International Classification of Headache Disorders, third edition (ICHD-3), primary ...
Acute ischaemic stroke management Recent randomized controlled trials (RCTs) comparing bridging intravenous thrombolysis (IVT) with tissue plasminogen activator (tPA) to direct endovascular treatment (EVT) for large-vessel occlusion (LVO) strokes within 4.5 hours of onset have failed to show inferiority of direct ...
Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1 Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and ...
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...
The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% ...
Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.